Access

Insight

Nature 436, 953-960 (18 August 2005) | doi:10.1038/nature04080; Published online 17 August 2005

Open Innovation Challenges

naturejobs

review article Challenges and successes in developing new therapies for hepatitis C

Raffaele De Francesco1 & Giovanni Migliaccio1

Top

Hepatitis C virus (HCV) will continue to be a serious global health threat for many years to come because of the chronic nature of the infection, its high prevalence and the significant morbidity of the resulting disease. Recently, a small number of molecules have produced encouraging results in proof-of-concept clinical trials. At the same time, preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs. Thus, combinations of multiple agents will be required to treat chronic HCV infection.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Hepatitis HCV variability, the immune system and resistance to antiviral drugs

Nature Reviews Gastroenterology & Hepatology News and Views (01 Jul 2009)

Virology Fresh assault on hepatitis C

Nature News and Views (13 Nov 2003)